{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T23:43:31Z","timestamp":1792280611980,"version":"4.4.0"},"reference-count":38,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2021,1,1]]},"DOI":"10.1001\/jamaoncol.2020.5774","type":"journal-article","created":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T12:26:07Z","timestamp":1605183967000},"page":"42","source":"Crossref","is-referenced-by-count":99,"title":["Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia"],"prefix":"10.1001","volume":"7","author":[{"given":"Ehab","family":"Atallah","sequence":"first","affiliation":[{"name":"Department of Medicine, Medical College of Wisconsin, Milwaukee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A.","family":"Schiffer","sequence":"additional","affiliation":[{"name":"Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerald P.","family":"Radich","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin P.","family":"Weinfurt","sequence":"additional","affiliation":[{"name":"Department of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Jie","family":"Zhang","sequence":"additional","affiliation":[{"name":"Division of Biostatistics, Medical College of Wisconsin, Milwaukee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Pinilla-Ibarz","sequence":"additional","affiliation":[{"name":"Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vamsi","family":"Kota","sequence":"additional","affiliation":[{"name":"Georgia Cancer Center, Augusta University Medical Center, Augusta"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Larson","sequence":"additional","affiliation":[{"name":"Department of Medicine and Comprehensive Cancer Center, University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph O.","family":"Moore","sequence":"additional","affiliation":[{"name":"Duke Cancer Institute, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Mauro","sequence":"additional","affiliation":[{"name":"Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W. N.","family":"Deininger","sequence":"additional","affiliation":[{"name":"Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, The University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Thompson","sequence":"additional","affiliation":[{"name":"Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian G.","family":"Oehler","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Wadleigh","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil P.","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California at San Francisco, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen K.","family":"Ritchie","sequence":"additional","affiliation":[{"name":"Division of Medicine, Department of Medical Oncology and Hematology, Weill Medical College of Cornell University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard T.","family":"Silver","sequence":"additional","affiliation":[{"name":"Division of Medicine, Department of Medical Oncology and Hematology, Weill Medical College of Cornell University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[{"name":"Georgia Cancer Center, Augusta University Medical Center, Augusta"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Visotcky","sequence":"additional","affiliation":[{"name":"Division of Biostatistics, Medical College of Wisconsin, Milwaukee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arielle","family":"Baim","sequence":"additional","affiliation":[{"name":"Department of Medicine, Medical College of Wisconsin, Milwaukee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Harrell","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bret","family":"Helton","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Horowitz","sequence":"additional","affiliation":[{"name":"Department of Medicine, Medical College of Wisconsin, Milwaukee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn E.","family":"Flynn","sequence":"additional","affiliation":[{"name":"Department of Medicine, Medical College of Wisconsin, Milwaukee"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"24","key":"coi200084r1","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population.","volume":"34","author":"Bower","year":"2016","journal-title":"J Clin Oncol"},{"issue":"23","key":"coi200084r2","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"issue":"11","key":"coi200084r3","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1200\/JCO.2003.12.154","article-title":"Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study.","volume":"21","author":"Hahn","year":"2003","journal-title":"J Clin Oncol"},{"issue":"2","key":"coi200084r4","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.leukres.2012.10.021","article-title":"Tyrosine-kinase inhibitors and patient-reported outcomes in chronic myeloid leukemia: a systematic review.","volume":"37","author":"Efficace","year":"2013","journal-title":"Leuk Res"},{"issue":"11","key":"coi200084r5","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"issue":"4","key":"coi200084r6","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"issue":"21","key":"coi200084r7","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1182\/blood.V122.21.255.255","article-title":"Long term follow-up after imatinib cessation for patients in deep molecular response: the update results of the STIM1 Study.","volume":"122","author":"Mahon","year":"2013","journal-title":"Blood"},{"issue":"5","key":"coi200084r8","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","article-title":"Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.","volume":"32","author":"Rousselot","year":"2014","journal-title":"J Clin Oncol"},{"issue":"21","key":"coi200084r10","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1182\/blood.V122.21.4003.4003","article-title":"Results from the Korean Imatinib Discontinuation Study (KIDS): updated data with 14-month median follow up.","volume":"122","author":"Yj","year":"2013","journal-title":"Blood"},{"issue":"21","key":"coi200084r11","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1182\/blood.V122.21.654.654","article-title":"Preliminary report of the STIM2 Study: a multicenter stop imatinib trial for chronic phase chronic myeloid leukemia de novo patients on imatinib.","volume":"122","author":"Mahon","year":"2013","journal-title":"Blood"},{"issue":"1","key":"coi200084r12","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1186\/s12885-018-4273-1","article-title":"Design and rationale for the Life After Stopping Tyrosine Kinase Inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia.","volume":"18","author":"Atallah","year":"2018","journal-title":"BMC Cancer"},{"issue":"2","key":"coi200084r13","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jmoldx.2013.10.007","article-title":"Detection and quantification of BCR-ABL1 fusion transcripts by droplet digital PCR.","volume":"16","author":"Jennings","year":"2014","journal-title":"J Mol Diagn"},{"issue":"2","key":"coi200084r14","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support.","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"issue":"9","key":"coi200084r15","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s00277-012-1458-6","article-title":"Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals?","volume":"91","author":"Efficace","year":"2012","journal-title":"Ann Hematol"},{"issue":"11","key":"coi200084r16","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.jclinepi.2010.04.011","article-title":"The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008.","volume":"63","author":"Cella","year":"2010","journal-title":"J Clin Epidemiol"},{"issue":"11","key":"coi200084r17","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.jclinepi.2010.04.012","article-title":"Relative to the general US population, chronic diseases are associated with poorer health-related quality of life as measured by the Patient-Reported Outcomes Measurement Information System (PROMIS).","volume":"63","author":"Rothrock","year":"2010","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"coi200084r18","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jclinepi.2010.11.018","article-title":"Minimally important differences were estimated for six PROMIS-Cancer scales in advanced-stage cancer patients.","volume":"64","author":"Yost","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"25","key":"coi200084r19","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1200\/JCO.2014.55.6910","article-title":"Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome?","volume":"32","author":"Richter","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"coi200084r20","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1037\/0022-006X.57.1.148","article-title":"A strategy to use soft data effectively in randomized controlled clinical trials.","volume":"57","author":"Kraemer","year":"1989","journal-title":"J Consult Clin Psychol"},{"issue":"3","key":"coi200084r22","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1200\/JCO.2016.68.2914","article-title":"Long-term follow-up of the French Stop Imatinib (STIM1) study in patients with chronic myeloid leukemia.","volume":"35","author":"Etienne","year":"2017","journal-title":"J Clin Oncol"},{"issue":"6","key":"coi200084r23","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol"},{"issue":"7","key":"coi200084r24","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/jnci\/djw003","article-title":"Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in chronic phase after generic entry of imatinib in the United States.","volume":"108","author":"Padula","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"coi200084r25","doi-asserted-by":"crossref","first-page":"468","DOI":"10.14694\/EDBK_175712","article-title":"Chronic myeloid leukemia: what every practitioner needs to know in 2017.","volume":"37","author":"Khoury","year":"2017","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"5","key":"coi200084r26","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1002\/cam4.2087","article-title":"Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation.","volume":"8","author":"Bernardi","year":"2019","journal-title":"Cancer Med"},{"issue":"22","key":"coi200084r27","doi-asserted-by":"crossref","first-page":"6606","DOI":"10.1158\/1078-0432.CCR-18-3373","article-title":"Evaluation of residual disease and TKI duration are critical predictive factors for molecular recurrence after stopping imatinib first-line in chronic phase CML patients.","volume":"25","author":"Nicolini","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"10","key":"coi200084r28","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/ajh.24120","article-title":"Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study.","volume":"90","author":"Mori","year":"2015","journal-title":"Am J Hematol"},{"issue":"9","key":"coi200084r29","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1634\/theoncologist.2018-0831","article-title":"Exploring patient decision making regarding discontinuation of tyrosine kinase inhibitors for chronic myeloid leukemia.","volume":"24","author":"Flynn","year":"2019","journal-title":"Oncologist"},{"issue":"4","key":"coi200084r30","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/s41375-019-0647-x","article-title":"Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission.","volume":"34","author":"Pagani","year":"2020","journal-title":"Leukemia"},{"issue":"12","key":"coi200084r31","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1038\/s41375-018-0264-0","article-title":"Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells.","volume":"32","author":"Ross","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"coi200084r32","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13045-016-0293-y","article-title":"Telomere length shortening is associated with treatment-free remission in chronic myeloid leukemia patients.","volume":"9","author":"Caocci","year":"2016","journal-title":"J Hematol Oncol"},{"issue":"6","key":"coi200084r33","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1007\/s00432-019-02894-3","article-title":"Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia.","volume":"145","author":"Cortes","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"issue":"18","key":"coi200084r34","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1002\/cncr.28758","article-title":"Ambulatory cancer and US general population reference values and cutoff scores for the functional assessment of cancer therapy.","volume":"120","author":"Pearman","year":"2014","journal-title":"Cancer"},{"issue":"2","key":"coi200084r35","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/s41375-019-0563-0","article-title":"Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy.","volume":"34","author":"Efficace","year":"2020","journal-title":"Leukemia"},{"issue":"8","key":"coi200084r36","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.clml.2019.05.007","article-title":"Musculoskeletal pain in patients with chronic myeloid leukemia after tyrosine kinase inhibitor therapy cessation.","volume":"19","author":"Kota","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"coi200084r37","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1007\/s00520-016-3297-9","article-title":"The association between clinician-based Common Terminology Criteria for Adverse Events (CTCAE) and patient-reported outcomes (PRO): a systematic review.","volume":"24","author":"Atkinson","year":"2016","journal-title":"Support Care Cancer"},{"key":"coi200084r38","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1182\/blood-2019-125736","article-title":"Tyrosine kinase inhibitor therapy discontinuation in clinical practice in chronic myeloid leukemia\u2014a US physician survey conducted after guideline updates.","volume":"134","author":"Atallah","year":"2019","journal-title":"Blood"},{"key":"coi200084r9","author":"Rea"},{"key":"coi200084r21","volume-title":"Linear Mixed Models for Longitudinal Data","author":"Verbeke","year":"2000"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2772842\/jamaoncology_atallah_2020_oi_200084_1609897940.7478.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T11:29:52Z","timestamp":1611228592000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2772842"}},"subtitle":["A Nonrandomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2021,1,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2020.5774","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1,1]]}}}